May 28, 2019 9:09 pm

Health Canada suspends Biocell breast implants due to increased cancer risk

WATCH ABOVE: How safe are breast implants?


Health Canada has suspended the licences for Biocell breast implants because of an increased cancer risk.

The department says it has completed an update to a safety review, which was launched two years ago, and suspended the licences for Allergan’s Biocell macro-textured breast implants because the potential risks associated with them outweigh their benefits.

READ MORE: How safe are breast implants? Women warn of risks, share their symptoms

It says in a statement that it has been notified of 26 confirmed Canadian cases of breast-implant-associated anaplastic large cell lymphoma, of which 22 involve Allergan’s Biocell breast implants, although no cases have been reported with any smooth surface implants.

It says Allergan has agreed to voluntarily recall unused Biocell devices from the Canadian market.

WATCH: Winnipeg woman wants others to be warned about breast implants

Story continues below

Health Canada says breast-implant-associated anaplastic large cell lymphoma is a rare type of non-Hodgkin lymphoma, a cancer that affects the immune system, which may develop many months or years after a breast implant procedure.

It is not a cancer of the breast tissue and usually presents as an accumulation of fluid between the implant and the surrounding tissue.

READ MORE: Health Canada moving to ban textured breast implants over cancer risk

Health Canada says its cause is unknown.

The department says if you have an Allergan Biocell breast implant or another type of breast implant, removing them is not recommended if you do not have any symptoms.

WATCH: Breast cancer risk from implants

It says patients should discuss the risks and benefits of removal with their health-care professional, and anyone who doesn’t know what type of breast implant they have should speak with the health-care provider who did the surgery.

© 2019 The Canadian Press

Report an error


Want to discuss? Please read our Commenting Policy first.